ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
PROMACTA(엘트롬보파그) 정제는 경구용 저분자 트롬보포에틴(TPO) 수용체 작용제인 엘트롬보파그 올라민(Eltrombopag Olamine)을 함유하고 있습니다. 미국에서는 PROMACTA, 미국 외 대부분의 국가에서는 Revolade라는 브랜드명으로 판매되고 있습니다. 이 약은 만성 ITP라고 불리는 특정 혈액 질환과 만성 C형 간염 환자의 혈소판 수치 저하를 치료하는 데 사용됩니다. 혈소판은 혈전을 형성하고 출혈을 예방하는 데 필요한 혈액 세포의 일종입니다. 엘트롬보패그는 혈소판 수를 증가시켜 출혈 위험을 감소시킵니다. 엘트롬보패그는 체내에서 혈소판을 생성하는 일종의 천연 물질(트롬보포에틴)처럼 작용합니다.
6세 이상의 대부분의 성인 및 소아 환자는 프로맥타 1일 1회 50mg, 1-5세 소아 환자는 1일 1회 25mg으로 시작해야 합니다. 간손상 환자 및 일부 동남아시아계 혈통의 환자들은 용량 감소가 필요합니다. 혈소판 수를 50×109/L 이상으로 유지하도록 조절합니다. 엘트롬보패그는 경구용 저분자 TPO 수용체 작용제이며, 인간 TPO 수용체의 막투과성 도메인과 상호 작용하여 골수 전구세포에서 거핵세포의 증식과 분화를 유도하는 신호 전달 캐스케이드를 개시합니다.
주요 7개국의 PROMACTA 시장에 대해 조사했으며, 시장의 개요와 2023-2032년 판매 예측 데이터, 경쟁 구도 및 국가별 동향 등을 제공하고 있습니다.
목차
제1장 리포트의 서론
제2장 면역성 혈소판 감소증(ITP)에 대한 PROMACTA의 개요
제품 상세
임상 개발
임상 연구
임상시험 정보
안전성과 유효성
규제상 마일스톤
기타 개발 활동
제품 개요
제3장 경쟁 구도(출시 치료법)
제4장 경쟁 구도(후기 단계 신규 치료법)
제5장 PROMACTA 시장 평가
ITP에 대한 PROMACTA의 시장 전망
주요 7개국 시장 분석
주요 7개국에서 ITP에 대한 PROMACTA의 시장 규모
국가별 시장 분석
미국
독일
영국
제6장 SWOT 분석
제7장 애널리스트의 견해
제8장 부록
제9장 DelveInsight의 서비스 내용
제10장 면책사항
제11장 DelveInsight 소개
제12장 리포트 구입 옵션
KSA
영문 목차
영문목차
“"PROMACTA Drug Insight and Market Forecast - 2032" ” report provides comprehensive insights about PROMACTA for immune thrombocytopenic purpura (ITP) in the seven major markets. A detailed picture of the PROMACTA for ITP in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the PROMACTA for ITP. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the PROMACTA market forecast analysis for ITP in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ITP.
Drug Summary:
PROMACTA (eltrombopag) tablets contain eltrombopag olamine, small molecule thrombopoietin (TPO) receptor agonist for oral administration. This is marketed under the brand name PROMACTA in the US and Revolade in most countries outside the US. This medication is used to treat low platelet levels in people who have a certain blood disorder called chronic ITP or who have chronic hepatitis C. It may also treat people with a certain blood disorder (aplastic anemia). Platelets are a type of blood cell needed to form blood clots and prevent bleeding. Eltrombopag decreases your risk of bleeding by increasing the number of platelets. Eltrombopag acts like a certain natural substance (thrombopoietin) that causes the body to produce platelets.
Dosage
Persistent or chronic ITP: Initiate PROMACTA at 50 mg once daily for most adult and pediatric patients 6 years and older and at 25 mg once daily for pediatric patients aged 1-5 years. Dose reductions are needed for patients with hepatic impairment and some patients of East-/Southeast Asian ancestry. Adjust to maintain platelet count greater than or equal to 50 × 109/L. Do not exceed 75 mg per day.
Mechanism of action
Eltrombopag is an orally bioavailable, small-molecule TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor and initiates signaling cascades that induce proliferation and differentiation of megakaryocytes from bone marrow progenitor cell.
Scope of the Report:
The report provides insights into:
A comprehensive product overview including the PROMACTA description, mechanism of action, dosage and administration, research and development activities in immune thrombocytopenic purpura (ITP).
Elaborated details on PROMACTA regulatory milestones and other development activities have been provided in this report.
The report also highlights the PROMACTA research and development activities in ITP across the United States, Europe and Japan.
The report also covers the patents information with expiry timeline around PROMACTA.
The report contains forecasted sales of PROMACTA for ITP till 2032.
Comprehensive coverage of the late-stage emerging therapies for ITP.
The report also features the SWOT analysis with analyst views for PROMACTA in ITP.
Methodology:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
PROMACTA Analytical Perspective by DelveInsight
In-depth PROMACTA Market Assessment
This report provides a detailed market assessment of PROMACTA for immune thrombocytopenic purpura (ITP) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
PROMACTA Clinical Assessment
The report provides the clinical trials information of PROMACTA for ITP covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights:
In the coming years, the market scenario for immune thrombocytopenic purpura (ITP) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence PROMACTA dominance.
Other emerging products for ITP are expected to give tough market competition to PROMACTA and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of PROMACTA in ITP.
Our in-depth analysis of the forecasted sales data of PROMACTA from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the PROMACTA in ITP.
Key Questions:
What is the product type, route of administration and mechanism of action of PROMACTA?
What is the clinical trial status of the study related to PROMACTA in immune thrombocytopenic purpura (ITP) and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the PROMACTA development?
What are the key designations that have been granted to PROMACTA for ITP?
What is the forecasted market scenario of PROMACTA for ITP?
What are the forecasted sales of PROMACTA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
What are the other emerging products available and how are these giving competition to PROMACTA for ITP?
Which are the late-stage emerging therapies under development for the treatment of ITP?
